Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2393

1.

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.

Osteoporos Int. 2009 Aug;20(8):1429-37. doi: 10.1007/s00198-008-0816-7. Epub 2008 Dec 20.

2.

A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.

Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T.

Bone. 2009 Jun;44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. Epub 2009 Mar 2.

PMID:
19264155
3.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

4.

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.

Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE.

Bone. 2005 Nov;37(5):651-4. Epub 2005 Aug 25.

PMID:
16126016
5.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
6.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

7.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
8.

Three years of treatment with minodronate in patients with postmenopausal osteoporosis.

Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T.

J Bone Miner Metab. 2012 Jul;30(4):439-46. doi: 10.1007/s00774-011-0332-2. Epub 2011 Dec 2.

9.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
10.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.

Curr Med Res Opin. 2005 Mar;21(3):391-401.

PMID:
15811208
11.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7.

PMID:
18950736
12.

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.

Am J Med. 2000 Sep;109(4):267-76.

PMID:
10996576
13.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
14.

Minodronate for the treatment of osteoporosis.

Kubo T, Shimose S, Matsuo T, Fujimori J, Ochi M.

Drugs Today (Barc). 2010 Jan;46(1):33-7. doi: 10.1358/dot.2010.46.1.1437707.

PMID:
20200694
15.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
16.

Beyond daily dosing: clinical experience.

Cooper C.

Bone. 2006 Apr;38(4 Suppl 1):S13-7. Epub 2006 Mar 7. Review.

PMID:
16520105
17.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
18.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R.

Osteoporos Int. 2000;11(1):83-91.

PMID:
10663363
19.

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.

Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T.

Osteoporos Int. 2012 Jun;23(6):1737-45. doi: 10.1007/s00198-011-1782-z. Epub 2011 Sep 20.

20.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

Items per page

Supplemental Content

Write to the Help Desk